ONCOLOGY · LUNG CANCER
EIK1001 non-small cell lung cancer study
A Phase 2 study combining EIK1001 with pembrolizumab and chemotherapy.
Study overview
This Phase 2 clinical study is evaluating EIK1001 in combination with pembrolizumab and chemotherapy for people with Stage 4 non-small cell lung cancer. Stage 4 means the cancer has spread beyond its original location. The study protocol defines the required cancer type, disease findings, previous treatments, laboratory values, and other eligibility criteria.
What researchers are evaluating
Researchers are studying the safety, tolerability, and anticancer activity of the investigational combination. Pembrolizumab is an immunotherapy that helps the immune system recognize cancer cells, while chemotherapy works through different mechanisms. EIK1001 is investigational, and its benefits and risks are not fully established. Study procedures may include physical examinations, blood tests, imaging, tumor assessments, medication reviews, and careful monitoring for side effects.
Considering participation
Eligibility may depend on tumor characteristics, treatment history, current medicines, overall health, organ function, and protocol-defined test results. Enrollment availability can change. Screening does not guarantee participation, and contacting California Research Institute does not obligate anyone to enroll.
Participation is voluntary. Before enrollment, the research team explains the study treatment, required visits, possible risks, potential benefits, alternatives, privacy protections, and participant rights through informed consent. Patients may discuss the study with their oncologist, family, or another trusted adviser before deciding.
For current information, call (323) 660-6200 or email trials@caresinst.org. Please do not email medical records, insurance information, or other sensitive health details. This page provides general education and does not replace medical advice.
The study coordinator can explain current availability and the initial screening process.